Background: Parkinson’s disease (PD) is a chronic, progressive disorder for which there is no satisfactory long-term treatment.Focal neuromodulation with repetitive transcranial magnetic stimulation ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Journal: Clinical Neurology and Neurosurgery 140:73-78 (2015)
Authors: O.S Cohen, Y Orlev, G Yahalom, R Amiaz, Z Nitsan, L Ephraty, A Rigbi, C Shabat, A Zangen, S Hassin-Baer
Repetitive transcranial magnetic stimulation (rTMS), using standard coils, provided symptomatic benefits in patients with Parkinson’s Disease (PD). In this group of investigators’ previous exploratory studies, using the newly developed Hesed coil (providing deeper rTMS; dTMS) high frequesncy (HF), excitatory dTMS over the primary motor cortex (M1), did not achieve sufficient beneficial effect for PD symptoms, while low frequency (LF) inhibitory stimulation was mildly beneficial.
To further investigate the optimal dTMS stimulation parameters for PD patients, and to assess whether there is an added value for dual stimulation, consisting of HF dTMS over the prefrntal cortex (PFC) along with LF M1 dTMS. The rational for the selection of the current stimulation parameters and sites lies on the previous studies that demonstrated an inhibitory effect of 1 Hz rTMS on the increased cortical activity in PD as well as dopamine release by PFC stimulation.
An open comparative active study of one month duration (12 sessions) of LF DTMS over M1 alone (n=9) or combined with HF PFC dTMS (M1-PFC, n=10). Outcome measures included the total and motor Unified Parkinson’s
Disease Rating Scale scores (T-UPDRS and M-UPDRS) and other variables, were collected at baseline and on days 30 and 60.
For the M1+PFC group, T-UPDRS score improved from baseline to day 30, by 15% (median: 52 points, decreased to 44, p=0.02, effect size: 0.51) and M-UPDRS score improved by 24% (median: 37 points decreased to 28, p=0.04, effect size: 0.47). The corresponding results for the M1 group were insignificant. Additionally, the between groups comparison, was insignificant.
dTMS consisting of M1 excitation with PFC inhibition improved PD motor symptoms but was not significantly superior to M1 dTMS alone. dTMS stimulation protocols should be further evaluated in larger scale controlled studies.